Abstract: Mobile device assisted secure computer network communications embodiments are presented that employ a mobile device (e.g., a mobile phone, personal digital assistant (PDA), and the like) to assist in user authentication. In general, this is accomplished by having a user enter a password into a client computer which is in contact with a server associated with a secure Web site. This password is integrated with a secret value, which is generated in real time by the mobile device. The secret value is bound to both the mobile device's hardware and the secure Web site being accessed, such that it is unique to both. In this way, a different secret value is generated for each secure Web site accessed, and another user cannot impersonate the user and log into a secure Web site unless he or she knows the password and possesses the user's mobile device simultaneously.

Abstract: The embodiments of the present disclosure disclose a method and apparatus for reducing the parameter transmission bandwidth. The parameter sender reduces the values of the parameters before sending the parameters to the parameter receiver. This scheme reduces the bandwidth consumed during parameter transmission, thus makes the transmission more efficient. The embodiment of the present disclosure also discloses a method for key exchange. This method reduces the values of the transmission parameters before sending the transmission parameters. This saves the bandwidth compared with the protocol in the prior art. Besides, the embodiment of the present disclosure discloses a system for key exchange. The parameter sender sends the transmission parameters to the bandwidth processing unit.

Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Abstract: Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. The compounds include azaindoles of the formula below [insert FIG. 6c] in which at least one of CR4, CR5, CR6 and CR7 is replaced by N, and the groups R1-R7 are defined as in claim 1.

Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Abstract: This invention is directed to processes for making substituted thiazoles. The substituted thiazole, ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia. This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.

Abstract: An exemplary optimistic protocol for a two-party transaction includes a setup sub-protocol that includes an authorized Diffie-Hellman key agreement, an exchange sub-protocol that includes sending a certificate from a sending party to a receiving party and sending a receipt from the receiving party to the sending party and a dispute sub-protocol that includes a dispute resolution mechanism for resolving disputes between the sending party and the receiving party due to sending of an invalid certificate, due to sending an invalid receipt, or due to abortion of the exchange sub-protocol. Other exemplary methods, systems, etc., are also disclosed.

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Abstract: This invention relates to a highly effective nanoparticle system for stabilizing near-infrared (near-IR) fluorescent dyes such as indocyanine (ICG) in order to enhance the dye's utility for biomedical application. This invention further relates to nanoparticles comprised of biodegradable polymer materials such as poly(dl-lactide-co-glycolide)(PLGA). The invention also relates to methods of preparing the nanoparticle-entrapped dyes, as well as methods for using them in bioimaging, diagnosis, and treatment of disease. The present invention also relates to compositions and kits comprising nanoparticle-entrapped dyes.

Abstract: Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.

Abstract: The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

Abstract: The present invention relates to an image forming apparatus comprising a movable image bearing member on which an image is formed; a movable intermediate transfer member, being in contact with said image bearing member, to which the image on said image bearing member is transferred; and a controlling means for starting a drive of said image bearing member after a drive of said intermediate transfer member is started.

Abstract: The present invention relates to an image forming apparatus comprising a movable image bearing member on which an image is formed; a movable intermediate transfer member, being in contact with said image bearing member, to which the image on said image bearing member is transferred; and a controlling means for starting a drive of said image bearing member after a drive of said intermediate transfer member is started.

Abstract: In order to suppress uneven densities in an image, an image forming apparatus includes an image bearing member; a first developing unit, including a first developer carrying member, for developing a first latent image formed on the image bearing member; a second developing unit, including a second developer carrying member, for developing a second latent image formed on the image bearing member after the first developing unit has developed the first latent image; and a rotary unit, for holding the first and the second developing units and for moving the first and the second developing unit to positions opposite said image bearing member. Upon the reception of an image forming signal at the image forming apparatus, the first and the second developer carrying members are rotated before the first latent image on the image bearing member is developed.

Abstract: This invention is directed to processes for making substituted thiazoles. The substituted thiazole, ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia. This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.

Abstract: This invention is directed to processes for making substituted thiazoles. The substituted thiazole, ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia. This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.

Abstract: The objective of the present invention is to suppress uneven densities in an image, and therefore, the present invention provides an image forming apparatus including:

Abstract: A data converting apparatus and process for converting outline representations of a character into its bit mapped form using two buffers one being for the bit mapped form of the character symbol and the other for the chain-code representation of the outline of the character are disclosed. Three steps are utilized in the process. The first step draws the character outline on to the drawing buffer and generates the chain-code representation with flags to indicate contour collisions. The contours are then scanned one more time to add missing flags on the chain-code representation. Finally, the inside part of the contour on the drawing buffer is filled using the chain-code representations of the contour, to provide a filled character.